[Huangjing Zanyu Capsule enhances sperm mitochondrial membrane potential in asthenozoospermia patients]

Zhonghua Nan Ke Xue. 2017 Dec;23(12):1116-1120.
[Article in Chinese]

Abstract

Objective: To observe the effect of Huangjing Zanyu Capsule (HZC) on sperm mitochondrial membrane potential (MMP) in asthenozoospermia patients.

Methods: We assigned 70 asthenozoospermia patients to a treatment group (n = 39) and a control group (n = 31), the former treated with oral HZC at the dose of 4 capsules tid for 3 months while the latter left untreated. We obtained semen parameters from the patients and detected their sperm mitochondrial membrane potentials (MMP) by JC-1 staining and flow cytometry before and after medication, followed by comparison between the two groups.

Results: The total effectiveness rate was 71.05% in the treatment group and natural pregnancy was achieved in 3 cases during the medication. A total of 35 patients in the treatment group and 30 controls completed all the laboratory examinations after a 3-month observation. Compared with the controls, the patients treated with HZC exhibited significant improvement after medication in MMP (variation value: [1.19 ± 10.36]% vs [20.28 ± 14.21]%, P <0.01), total sperm motility (variation value: [3.46 ± 8.67]% vs [20.68 ± 14.12]%, P <0.01), the percentage of progressively motile sperm (variation value: [2.26 ± 8.29]% vs [17.58 ± 12.73]%, P <0.01), and the percentage of morphologically normal sperm (variation value: [0.23 ± 3.48]% vs [3.37 ± 3.99]%, P <0.01). MMP was significantly correlated with total sperm motility (r = 0.69, P <0.01), progressive sperm motility (r = 0.75, P <0.01) and normal sperm morphology (r = 0.26, P <0.01).

Conclusions: Huangjing Zanyu Capsule can enhance sperm mitochondrial membrane potential and sperm mitochondrial function, thus improving total sperm motility, progressive sperm motility and normal sperm morphology. It is safe and effective for the treatment of asthenospermia.

目的: 观察黄精赞育胶囊对弱精子症患者精子线粒体膜电位的影响及临床疗效。 方法: 弱精子症患者70例分药物治疗组(n=39)和空白对照组(n=31)做队列观察研究。药物治疗组予黄精赞育胶囊口服3个月,1次4粒,每日3次。服用时可备孕,期间若配偶怀孕则停止用药。空白对照组不予药物干预。观察初次就诊和3个月后精液参数变化,及JC-1染色后流式细胞仪检测精子线粒体膜电位(MMP)值的变化。 结果: 两组各失随访1例。药物治疗组总有效率为71.05%,服药过程中3例患者女方自然妊娠。药物治疗组35例患者完成观察期结束后检查,MMP%、精子总活力、前向运动精子百分率(PR%)、精子形态均有改善,其变化值较空白对照组30例患者的测定值有显著差异(P<0.01),分别为△MMP%: (20.28±14.21)% vs (1.19±10.36)%; △PR%: (17.58±12.73)% vs (2.26±8.29)%;△总活力: (20.68±14.12)% vs (3.46±8.67)%;△正常形态精子百分率: (3.37±3.99)% vs (0.23±3.48)%。MMP%与精子总活力(r=0.69)、PR%(r=0.75)、正常形态精子百分率(r=0.26)具有显著相关性(P<0.01)。结论: 黄精赞育胶囊能提高精子MMP值,改善线粒体功能,从而有效增加精子活力及PR%并改善精子形态,对治疗弱精子症安全有效。.

Keywords: asthenozoospermia; mitochondrial membrane potential; Huangjing Zanyu Capsule.

MeSH terms

  • Asthenozoospermia / drug therapy*
  • Capsules
  • Case-Control Studies
  • Drugs, Chinese Herbal / administration & dosage
  • Drugs, Chinese Herbal / therapeutic use*
  • Female
  • Flow Cytometry
  • Humans
  • Male
  • Membrane Potential, Mitochondrial / drug effects*
  • Membrane Potential, Mitochondrial / physiology
  • Pregnancy
  • Semen / drug effects
  • Sperm Motility / drug effects
  • Spermatozoa / drug effects*
  • Spermatozoa / ultrastructure
  • Staining and Labeling

Substances

  • Capsules
  • Drugs, Chinese Herbal